Literature DB >> 32496241

Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?

Praveen Balabaskaran Nina1, Aditya Prasad Dash2.   

Abstract

Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.

Entities:  

Keywords:  COVID-19; Chloroquine; Hydroxychloroquine; Prophylaxis

Mesh:

Substances:

Year:  2020        PMID: 32496241     DOI: 10.4103/ijph.IJPH_496_20

Source DB:  PubMed          Journal:  Indian J Public Health        ISSN: 0019-557X


  7 in total

Review 1.  Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.

Authors:  Sreedhar Amere Subbarao
Journal:  Inflammopharmacology       Date:  2021-03-15       Impact factor: 5.093

2.  Situation of India in the COVID-19 Pandemic: India's Initial Pandemic Experience.

Authors:  Azizah F Siddiqui; Manuel Wiederkehr; Liudmila Rozanova; Antoine Flahault
Journal:  Int J Environ Res Public Health       Date:  2020-12-02       Impact factor: 3.390

3.  Demand of COVID-19 medicines without prescription among community pharmacies in Jodhpur, India: Findings and implications.

Authors:  Siddhartha Dutta; Rimple J Kaur; Pankaj Bhardwaj; Sneha Ambwani; Brian Godman; Pallavi A Jha; Sanchi Sukhija; Suman S Venkatesh; Halyna Lugova; Salequl Islam; Jaykaran Charan; Mainul Haque
Journal:  J Family Med Prim Care       Date:  2022-02-16

4.  Epidemiological determinants of COVID-19 in the police personnel: A cross-sectional study.

Authors:  Rupali Sabale; Gajanan Velhal; Vandana Tripathi; Saurabh Tripathi
Journal:  J Family Med Prim Care       Date:  2022-01-31

5.  Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.

Authors:  Janna Krueger; Francois Santinon; Alexandra Kazanova; Mark E Issa; Bruno Larrivee; Richard Kremer; Catalin Milhalcioiu; Christopher E Rudd
Journal:  PLoS One       Date:  2021-06-28       Impact factor: 3.240

Review 6.  COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.

Authors:  Hussain Ahmed Raza; Javeria Tariq; Vikas Agarwal; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-01-01       Impact factor: 2.631

7.  Side effects of hydroxychloroquine prophylaxis against COVID-19 in healthcare workers.

Authors:  Prashant Kumar Dixit; Salil Gupta; Ajay Shankar Prasad; Kinshuk Kohli; Parthasarathi Ghana
Journal:  Med J Armed Forces India       Date:  2021-07-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.